• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Illumina Inc.

    5/16/25 4:39:41 PM ET
    $ILMN
    Medical Specialities
    Health Care
    Get the next $ILMN alert in real time by email
    SD 1 a2025sdform.htm SD Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM SD

    SPECIALIZED DISCLOSURE REPORT
    ilmnlogoa22.jpg
    Illumina, Inc.
    (Exact name of the registrant as specified in its charter)

    001-35406
    (Commission File Number)
    Delaware 33-0804655
    (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)
    5200 Illumina Way, San Diego, CA 92122
    (Address of principal executive offices) (Zip code)
    Kevin Pegels 858-202-4500
    (Name and telephone number, including area code, of the
    person to contact in connection with this report.)

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
    þRule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.



    Section 1 - Conflict Minerals Disclosure

    Illumina, Inc. (“Illumina”) develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function.

    Certain products manufactured by Illumina contain one or more of gold, tantalum, tin and tungsten (3TG). Illumina is committed to responsible sourcing practices that are designed to reduce the risk that our sourcing practices support conflict or human rights abuses in the Democratic Republic of Congo (DRC) or an adjoining country.

    Item 1.01 Conflict Minerals Disclosure and Report

    Illumina has concluded in good faith that during 2024,
    a)     Illumina manufactured products for which “conflict minerals” (as defined in item 1.01(d)(3) of Form SD) are necessary to the functionality or production.
    b)     Based on its reasonable country of origin inquiry, Illumina has reason to believe that its necessary conflict minerals may have originated in the Democratic Republic of the Congo or an adjoining country.

    In accord with Rule 13p-1 under the Securities Exchange Act of 1934, Illumina has filed this Specialized Disclosure Report on Form SD and the associated Conflict Minerals Report, and both reports are posted to a publicly available Internet site at www.illumina.com.

    Item 1.02 Exhibits

    The Conflict Minerals Report required by Item 1.01 is filed as Exhibit 1.01 to this Form SD.

    Section 2 - Exhibits

    Item 2.01 Exhibits

    Exhibit 1.01 - Conflict Minerals Report for the reporting period January 1, 2024 to December 31, 2024



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
    ILLUMINA, INC.
    Date: May 16, 2025By:/s/ Kevin Pegels
    Name:Kevin Pegels
    Title:Chief of Global Operations



    Exhibit Index
    Exhibit NumberDescription
    1.01
    Conflict Minerals Report for the reporting period January 1, 2024 to December 31, 2024

    Get the next $ILMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ILMN

    DatePrice TargetRatingAnalyst
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    12/11/2024$190.00 → $165.00Buy → Neutral
    Citigroup
    11/12/2024$156.00Equal-Weight
    Morgan Stanley
    10/17/2024$180.00Hold → Buy
    HSBC Securities
    8/28/2024Hold → Buy
    Argus
    More analyst ratings

    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:20:13 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Chief Executive Officer Thaysen Jacob bought $998,674 worth of shares (12,350 units at $80.86), increasing direct ownership by 17% to 83,390 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:18:28 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Thaysen Jacob bought $991,672 worth of shares (7,330 units at $135.29), increasing direct ownership by 97% to 14,861 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      2/26/24 8:57:29 AM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Meister Keith A. was granted 3,780 shares, increasing direct ownership by 605% to 4,405 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/23/25 5:17:19 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Director Arnold Frances was granted 3,780 shares, increasing direct ownership by 22% to 20,907 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/23/25 5:10:20 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Director Dorsa Caroline was granted 3,780 shares, increasing direct ownership by 33% to 15,194 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/23/25 5:09:24 PM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup reiterated coverage on Illumina with a new price target

      Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously

      3/4/25 8:10:42 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Illumina downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Illumina from Buy to Hold and set a new price target of $100.00

      2/28/25 9:03:13 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Illumina downgraded by Barclays with a new price target

      Barclays downgraded Illumina from Equal Weight to Underweight and set a new price target of $100.00 from $130.00 previously

      2/10/25 6:59:21 AM ET
      $ILMN
      Medical Specialities
      Health Care